{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:00:54Z","timestamp":1788436854353,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"Universit\u00e4t Z\u00fcrich","doi-asserted-by":"publisher","award":["Clinical research priority programme CRPP \"Artifical Intelligence in oncological imaging\""],"award-info":[{"award-number":["Clinical research priority programme CRPP \"Artifical Intelligence in oncological imaging\""]}],"id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Careful selection of malignant pleural mesothelioma (MPM) patients for curative treatment is of highest importance, as the multimodal treatment regimen is challenging for patients and harbors a high risk of substantial toxicity. Radiomics\u2014a quantitative method for image analysis\u2014has shown its prognostic ability in different tumor entities and could therefore play an important role in optimizing patient selection for radical cancer treatment. So far, radiomics as a prognostic tool in MPM was not investigated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>This study is based on 72 MPM patients treated with surgery in a curative intent at our institution between 2009 and 2017. Pre-treatment Fluorine-18 fluorodeoxyglucose (FDG) PET and CT scans were used for radiomics outcome modeling. After extraction of 1404 CT and 1410 FDG PET features from each image, a preselection by principal component analysis was performed to include only robust, non-redundant features for the cox regression to predict the progression-free survival (PFS) and the overall survival (OS). Results were validated on a separate cohort. Additionally, SUVmax and SUVmean, and volume were tested for their prognostic ability for PFS and OS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>For the PFS a concordance index (c-index) of 0.67 (95% CI 0.52\u20130.82) and 0.66 (95% CI 0.57\u20130.78) for the training cohort (<jats:italic>n<\/jats:italic> = 36) and internal validation cohort (<jats:italic>n<\/jats:italic> = 36), respectively, were obtained for the PET radiomics model. The PFS advantage of the low-risk group translated also into an OS advantage. On CT images, no radiomics model could be trained. SUV max and SUV mean were also not prognostic in terms of PFS and OS.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We were able to build a successful FDG PET radiomics model for the prediction of PFS in MPM. Radiomics could serve as a tool to aid clinical decision support systems for treatment of MPM in future.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13550-020-00669-3","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T12:06:02Z","timestamp":1594641962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-6152","authenticated-orcid":false,"given":"M.","family":"Pavic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bogowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mayinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G. C.","family":"Kroeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Friess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Frauenfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Andratschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Weder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Tanadini-Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"issue":"18","key":"669_CR1","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1016\/j.ejca.2007.09.018","volume":"43","author":"A Marinaccio","year":"2007","unstructured":"Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante P, et al. Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer. 2007;43(18):2722\u20138.","journal-title":"Eur J Cancer."},{"issue":"8","key":"669_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","volume":"66","author":"JM Mazurek","year":"2017","unstructured":"Mazurek JM, Syamlal G, Wood JM, Hendricks SA, Weston A. Malignant mesothelioma mortality - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"18","key":"669_CR3","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1200\/JCO.2008.20.3943","volume":"27","author":"LM Krug","year":"2009","unstructured":"Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007\u201313.","journal-title":"J Clin Oncol."},{"key":"669_CR4","doi-asserted-by":"crossref","unstructured":"Thieke C, Nicolay NH, Sterzing F, Hoffmann H, Roeder F, Safi S, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiation oncology (London, England). 2015;10:267.","DOI":"10.1186\/s13014-015-0575-5"},{"issue":"16","key":"669_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","volume":"16","author":"RA Stahel","year":"2015","unstructured":"Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial. The Lancet Oncology. 2015;16(16):1651\u20138.","journal-title":"The Lancet Oncology."},{"key":"669_CR6","doi-asserted-by":"crossref","unstructured":"Kindler HL, Ismaila N, III SGA, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. 2018;36(13):1343-1373.","DOI":"10.1200\/JCO.2017.76.6394"},{"issue":"6","key":"669_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/JTO.0000000000000181","volume":"9","author":"HI Pass","year":"2014","unstructured":"Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC Staging Committee. J Thorac Oncol. 2014;9(6):856\u201364.","journal-title":"J Thorac Oncol."},{"issue":"1","key":"669_CR8","first-page":"145","volume":"16","author":"D Curran","year":"1998","unstructured":"Curran D, Sahmoud T, Therasse P. Meerbeeck Jv, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. 1998;16(1):145\u201352.","journal-title":"Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience."},{"issue":"2","key":"669_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S0022-5223(98)70274-0","volume":"115","author":"HI Pass","year":"1998","unstructured":"Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1998;115(2):310\u20137 discussion 7-8.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"11","key":"669_CR10","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","volume":"10","author":"I Opitz","year":"2015","unstructured":"Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen-Kim TDL, et al. A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 years' experience. J Thorac Oncol. 2015;10(11):1634\u201341.","journal-title":"J Thorac Oncol."},{"issue":"12","key":"669_CR11","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","volume":"11","author":"AK Nowak","year":"2016","unstructured":"Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11(12):2089\u201399.","journal-title":"J Thorac Oncol."},{"issue":"4","key":"669_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RGPM, Granton P, et al. Radiomics: Extracting more information from medical images using advanced feature analysis. European Journal of Cancer. 2012;48(4):441\u20136.","journal-title":"European Journal of Cancer."},{"issue":"1091","key":"669_CR13","first-page":"20170926","volume":"91","author":"SA Keek","year":"2018","unstructured":"Keek SA, Leijenaar RT, Jochems A. Woodruff HC. A review on radiomics and the future of theranostics for patient selection in precision medicine. 2018;91(1091):20170926.","journal-title":"A review on radiomics and the future of theranostics for patient selection in precision medicine."},{"key":"669_CR14","unstructured":"Zwanenburg A, Valli\u00e8res M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping.0(0):191145."},{"key":"669_CR15","doi-asserted-by":"crossref","unstructured":"Pavic M, Bogowicz M, Wurms X, Glatz S, Finazzi T, Riesterer O, et al. Influence of inter-observer delineation variability on radiomics stability in different tumor sites. Acta oncologica (Stockholm, Sweden). 2018;57(8):1070-4.","DOI":"10.1080\/0284186X.2018.1445283"},{"key":"669_CR16","unstructured":"USZ Medical Physics - Z-Rad. https:\/\/medical-physics-usz.github.io\/. Accessed 18 Apr 2020 ."},{"issue":"2","key":"669_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychological bulletin. 1979;86(2):420\u20138.","journal-title":"Psychological bulletin."},{"key":"669_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF02289447","volume":"30","author":"JL Horn","year":"1965","unstructured":"Horn JL. A RATIONALE AND TEST FOR THE NUMBER OF FACTORS IN FACTOR ANALYSIS. Psychometrika. 1965;30:179\u201385.","journal-title":"Psychometrika."},{"issue":"2","key":"669_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3892\/etm.2012.572","volume":"4","author":"T Terada","year":"2012","unstructured":"Terada T, Tabata C, Tabata R, Okuwa H, Kanemura S, Shibata E, et al. Clinical utility of 18-fluorodeoxyglucose positron emission tomography\/computed tomography in malignant pleural mesothelioma. Exp Ther Med. 2012;4(2):197\u2013200.","journal-title":"Exp Ther Med."},{"issue":"10","key":"669_CR20","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.acra.2017.03.006","volume":"24","author":"E Pena","year":"2017","unstructured":"Pena E, Ojiaku M, Inacio JR, Gupta A, Macdonald DB, Shabana W, et al. Can CT and MR Shape and Textural Features Differentiate Benign Versus Malignant Pleural Lesions? Acad Radiol. 2017;24(10):1277\u201387.","journal-title":"Acad Radiol."},{"issue":"2","key":"669_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257\u201360.","journal-title":"Ann Oncol."},{"issue":"2","key":"669_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1214\/aoms\/1177704583","volume":"33","author":"CB Bell","year":"1962","unstructured":"Bell CB. Mutual information and maximal correlation as measures of dependence. Ann Math Statist. 1962;33(2):587\u201395.","journal-title":"Ann Math Statist."},{"issue":"1","key":"669_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0167-8140(01)00444-3","volume":"62","author":"P Giraud","year":"2002","unstructured":"Giraud P, Elles S, Helfre S, De Rycke Y, Servois V, Carette MF, et al. Conformal radiotherapy for lung cancer: different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2002;62(1):27\u201336.","journal-title":"Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology."},{"key":"669_CR24","doi-asserted-by":"crossref","unstructured":"Riegel AC, Berson AM, Destian S, Ng T, Tena LB, Mitnick RJ, et al. Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET\/CT fusion. International Journal of Radiation Oncology*Biology*Physics. 2006;65(3):726-32.","DOI":"10.1016\/j.ijrobp.2006.01.014"},{"issue":"6","key":"669_CR25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2967\/jnumed.118.217612","volume":"60","author":"L Papp","year":"2019","unstructured":"Papp L, Rausch I, Grahovac M, Hacker M, Beyer T. Optimized Feature Extraction for Radiomics Analysis of (18)F-FDG PET Imaging. J Nucl Med. 2019;60(6):864\u201372.","journal-title":"J Nucl Med."},{"issue":"24","key":"669_CR26","doi-asserted-by":"publisher","first-page":"8736","DOI":"10.1088\/1361-6560\/61\/24\/8736","volume":"61","author":"M Bogowicz","year":"2016","unstructured":"Bogowicz M, Riesterer O, Bundschuh RA, Veit-Haibach P, Hullner M, Studer G, et al. Stability of radiomic features in CT perfusion maps. Physics in medicine and biology. 2016;61(24):8736\u201349.","journal-title":"Physics in medicine and biology."},{"issue":"2","key":"669_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1148\/radiol.2018172361","volume":"288","author":"R Berenguer","year":"2018","unstructured":"Berenguer R, Pastor-Juan MDR, Canales-Vazquez J, Castro-Garcia M, Villas MV, Mansilla Legorburo F, et al. Radiomics of CT Features May Be Nonreproducible and Redundant: Influence of CT Acquisition Parameters. Radiology. 2018;288(2):407\u201315.","journal-title":"Radiology."},{"key":"669_CR28","doi-asserted-by":"crossref","unstructured":"Espinasse M, Pitre-Champagnat S, Charmettant B, Bidault F, Volk A, Balleyguier C, et al. CT texture analysis challenges: influence of acquisition and reconstruction parameters: a comprehensive review. Diagnostics (Basel, Switzerland). 2020;10(5).","DOI":"10.3390\/diagnostics10050258"},{"issue":"4","key":"669_CR29","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.ijrobp.2018.05.053","volume":"102","author":"A Traverso","year":"2018","unstructured":"Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: a systematic review. International journal of radiation oncology, biology, physics. 2018;102(4):1143\u201358.","journal-title":"International journal of radiation oncology, biology, physics."},{"key":"669_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40336-018-0292-9","volume":"6","author":"PVD Lovinfosse","year":"2018","unstructured":"Lovinfosse PVD, Hustinx R, Hatt M. FDG PET radiomics: a review of the methodological aspects. Clin Transl Imaging. 2018;6:379\u201391.","journal-title":"Clin Transl Imaging."},{"issue":"13","key":"669_CR31","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1007\/s00259-019-04391-8","volume":"46","author":"A Zwanenburg","year":"2019","unstructured":"Zwanenburg A. Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis. European journal of nuclear medicine and molecular imaging. 2019;46(13):2638\u201355.","journal-title":"European journal of nuclear medicine and molecular imaging."},{"key":"669_CR32","volume-title":"CT radiomics and PET radiomics: ready for clinical implementation? Q J Nucl Med Mol Imaging","author":"M Bogowicz","year":"2019","unstructured":"Bogowicz M, Vuong D, Huellner MW, Pavic M, Andratschke N, Gabrys HS, et al. CT radiomics and PET radiomics: ready for clinical implementation? Q J Nucl Med Mol Imaging. 2019."},{"issue":"8","key":"669_CR33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2967\/jnumed.117.199935","volume":"59","author":"F Orlhac","year":"2018","unstructured":"Orlhac F, Boughdad S, Philippe C, Stalla-Bourdillon H, Nioche C, Champion L, et al. A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET. J Nucl Med. 2018;59(8):1321\u20138.","journal-title":"J Nucl Med."},{"issue":"6","key":"669_CR34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jclinepi.2014.12.014","volume":"68","author":"PC Austin","year":"2015","unstructured":"Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. J Clin Epidemiol. 2015;68(6):627\u201336.","journal-title":"J Clin Epidemiol."}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-020-00669-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-020-00669-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-020-00669-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T23:14:02Z","timestamp":1626131642000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-020-00669-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1186\/s13550-020-00669-3","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the local ethics committee (KEK-ZH-Nr. 2015-0171). As this study was of retrospective nature, a consent form was waived by the local ethics committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.H.: research grants and speaker\u2019s fees from GE Healthcare. N.A.: advisory duties for AstraZeneca, Deniopharm. Speaker\u2019s duty for AstraZeneca, Deniopharm, Brainlab, ViewRay. Research support by Brainlab, ViewRay. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}